Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06469801 · ClinicalTrials.gov registry record · NA
ECMO ABI Detection With Hyperfine
A NA study of Stroke, Acute and Extracorporeal Membrane Oxygenation Complication, sponsored by Children's Mercy Hospital Kansas City.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06469801: Recruiting NA study of Stroke, Acute and Extracorporeal Membrane Oxygenation Complication, sponsored by Children's Mercy Hospital Kansas City.
NCT06469801 is a NA study of Stroke, Acute and Extracorporeal Membrane Oxygenation Complication that is actively recruiting participants, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 30 participants, below the 629-participant average among 25 other Stroke, Acute trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06469801, a NA study of Stroke, Acute and Extracorporeal Membrane Oxygenation Complication, is actively recruiting participants, sponsored by Children's Mercy Hospital Kansas City.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.
Primary Outcome
Perform bedside MRI in pediatric ECMO patients treated in pediatric, cardiac, and neonatal intensive care units (ICUs) within 36 hours of cannulation. Determine rates of ABI (hypoxic, ischemic, cerebrovascular, and hemorrhagic injury along with assessment of cerebral edema and midline shift) in the pre- and peri-cannulation time periods. Correlate these imaging findings to rates of clinical neurological events (seizures, pupillary changes, focal neurological examination).
Conditions Studied
Interventions
- DEVICE Hyperfine
Study Locations (1)
Missouri
- Children's Mercy - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2026-07-01 |
| Phase | NA |
What NCT06469801 shows while recruiting
NCT06469801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 629-participant average among 25 other Stroke, Acute trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Stroke, Acute appearing as the primary indexed condition, and to 1 intervention - of which Hyperfine is the first listed.
NCT06469801 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06469801 about?
NCT06469801 is a clinical study titled "ECMO ABI Detection With Hyperfine". The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinic...
What is the current status of trial NCT06469801?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-07-23. Estimated completion is 2026-07-01.
What conditions does trial NCT06469801 study?
This clinical trial studies the following conditions: Stroke, Acute, Extracorporeal Membrane Oxygenation Complication, Hypoxia-Ischemia, Brain, Acute Brain Injury.
What interventions are being tested in trial NCT06469801?
The interventions under investigation include: Hyperfine (DEVICE).
Who is sponsoring clinical trial NCT06469801?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06469801 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06469801's enrollment target sits among peer trials
30 24th of 25 higher than 1 of 25 other Stroke, Acute trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke, Acute trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
RECRUITING · NA
-
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
RECRUITING · NA
-
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
RECRUITING · NA
-
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
RECRUITING · NA
-
Efficacy of a Telehealth Delivered Group Lifestyle Balance for People Post Stroke (tGLB-CVA)
RECRUITING · NA
-
EnDOvascular Therapy for Late WiNdow IschEmic Stroke Patients Selected bY AutoMatic Plain ComputErized Tomography
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI